JPRN-jRCT2080221113
Unknown
Phase 3
A multicenter, open-label, long-term safety study of aripiprazoleorally administered over 52 weeks in patients who complete a short-term treatment study of aripiprazole in pediatric patients with schizophrenia (031-09-003 study)
ConditionsSchizophrenia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Schizophrenia
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Enrollment
- 30
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients with a diagnosis of schizophrenia according to DSM\-IV\-TR
- •2\) Male and female patients aged 13\-17 years
- •3\) Patients completing the 031\-09\-003 study
Exclusion Criteria
- •1\) Patients who have a diagnosis of any other disease except schizophrenia, according to DSM\-IV\-TR
- •2\) Patients who fall under a contraindication listed in the ABILIFY package insert
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Peanut allergy studyEUCTR2017-001334-26-ITAIMMUNE THERAPEUTICS1,100
Unknown
Phase 3
ong-term Treatment Study of CDP870 without coadministration of MTX in Japanese RA patientsRheumatoid ArthritisJPRN-jRCT2080220676Astellas Pharma Inc.130
Unknown
Phase 3
ong-term Treatment Study of CDP870 as Add-on Medication to MTX in Japanese RA patientsRheumatoid ArthritisJPRN-jRCT2080220675Astellas Pharma Inc.222
Active, not recruiting
Not Applicable
A multicenter, single-arm, open-label safety study of lenalidomide plus dexamethasone in previously treated subjects with Multiple Myeloma.Previously treated subjects with Multiple MyelomaEUCTR2006-002517-12-ATCelgene International Sàrl1,400
Active, not recruiting
Not Applicable
Trial to assess the long-term safety of tretinoin clindamycin phosphate gel in patients from 12 to less than 18 years of age with acne vulgaris.Treatment of Acne vulgarisMedDRA version: 14.1Level: HLTClassification code 10000497Term: AcnesSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2010-022912-37-Outside-EU/EEAMedicis Pharmaceutical Corporation442